Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? 28 May Dr D Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.